HRP20220737T1 - Upalni biomarkeri za predviđanje odgovaranja na spoj fgf-18 - Google Patents

Upalni biomarkeri za predviđanje odgovaranja na spoj fgf-18 Download PDF

Info

Publication number
HRP20220737T1
HRP20220737T1 HRP20220737TT HRP20220737T HRP20220737T1 HR P20220737 T1 HRP20220737 T1 HR P20220737T1 HR P20220737T T HRP20220737T T HR P20220737TT HR P20220737 T HRP20220737 T HR P20220737T HR P20220737 T1 HRP20220737 T1 HR P20220737T1
Authority
HR
Croatia
Prior art keywords
fgf
compound
treatment
subject
sensitivity
Prior art date
Application number
HRP20220737TT
Other languages
English (en)
Croatian (hr)
Inventor
Christoph H. Ladel
Hans Guehring
Anne-Christine BAY-JENSEN
Morten Karsdal
Per Qvist
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20220737T1 publication Critical patent/HRP20220737T1/hr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HRP20220737TT 2017-09-29 2018-09-28 Upalni biomarkeri za predviđanje odgovaranja na spoj fgf-18 HRP20220737T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17194169 2017-09-29
EP18169317 2018-04-25
PCT/EP2018/076391 WO2019063756A1 (en) 2017-09-29 2018-09-28 INFLAMMATORY BIOMARKERS FOR PREDICTING REACTIVITY TO FGF-18 COMPOUND
EP18782012.1A EP3688468B1 (en) 2017-09-29 2018-09-28 Inflammatory biomarkers for predicting responsiveness to fgf-18 compound

Publications (1)

Publication Number Publication Date
HRP20220737T1 true HRP20220737T1 (hr) 2022-09-02

Family

ID=63722379

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220737TT HRP20220737T1 (hr) 2017-09-29 2018-09-28 Upalni biomarkeri za predviđanje odgovaranja na spoj fgf-18

Country Status (16)

Country Link
US (2) US11467169B2 (cg-RX-API-DMAC7.html)
EP (1) EP3688468B1 (cg-RX-API-DMAC7.html)
JP (1) JP7418324B2 (cg-RX-API-DMAC7.html)
CN (1) CN111164429B (cg-RX-API-DMAC7.html)
AU (1) AU2018343980B2 (cg-RX-API-DMAC7.html)
CA (1) CA3075713A1 (cg-RX-API-DMAC7.html)
DK (1) DK3688468T3 (cg-RX-API-DMAC7.html)
ES (1) ES2918249T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220737T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058848T2 (cg-RX-API-DMAC7.html)
IL (1) IL273574B2 (cg-RX-API-DMAC7.html)
LT (1) LT3688468T (cg-RX-API-DMAC7.html)
PL (1) PL3688468T3 (cg-RX-API-DMAC7.html)
RS (1) RS63292B1 (cg-RX-API-DMAC7.html)
SI (1) SI3688468T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019063756A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
EP1551426B1 (en) 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
WO2004043237A2 (en) 2002-11-08 2004-05-27 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
US8224579B2 (en) 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
JP2009257842A (ja) 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
US20100098775A1 (en) 2008-05-02 2010-04-22 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
EP2880179B1 (en) 2012-08-06 2017-12-13 Merck Patent GmbH Genetic markers for predicting responsiveness to fgf-18 compound
PL2880181T3 (pl) 2012-08-06 2019-03-29 Merck Patent Gmbh Biomarkery prognostyczne w zaburzeniach chrząstki
TW201536320A (zh) * 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
KR102434024B1 (ko) 2013-12-24 2022-08-22 아레스 트레이딩 에스.아. 알지네이트/콜라겐 히드로겔 중의 fgf-18 제형물
NZ721332A (en) 2013-12-24 2022-07-01 Ares Trading Sa Fgf-18 formulation in xyloglucan gels
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 fgf-18
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Also Published As

Publication number Publication date
US12332250B2 (en) 2025-06-17
US20210231680A1 (en) 2021-07-29
ES2918249T3 (es) 2022-07-14
AU2018343980B2 (en) 2025-04-10
DK3688468T3 (da) 2022-06-20
JP7418324B2 (ja) 2024-01-19
CA3075713A1 (en) 2019-04-04
PL3688468T3 (pl) 2022-07-18
US20230258659A1 (en) 2023-08-17
EP3688468A1 (en) 2020-08-05
EP3688468B1 (en) 2022-03-16
WO2019063756A1 (en) 2019-04-04
CN111164429A (zh) 2020-05-15
AU2018343980A1 (en) 2020-04-02
JP2020535423A (ja) 2020-12-03
IL273574B1 (en) 2024-09-01
CN111164429B (zh) 2024-08-09
RS63292B1 (sr) 2022-06-30
SI3688468T1 (sl) 2022-08-31
US11467169B2 (en) 2022-10-11
LT3688468T (lt) 2022-06-27
HUE058848T2 (hu) 2022-09-28
IL273574B2 (en) 2025-01-01
IL273574A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
Reinhardt et al. Bovine milk proteome: quantitative changes in normal milk exosomes, milk fat globule membranes and whey proteomes resulting from Staphylococcus aureus mastitis
Brownlow et al. The vascularity of atrophic non-unions
Steenland et al. PFOA and ulcerative colitis
Gremmel et al. Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb
Stephens et al. Differential proteoglycan and hyaluronan distribution in calcified aortic valves
Ito et al. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells
Jaffar et al. Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis
Rogler et al. Anemia in inflammatory bowel disease: an under-estimated problem?
HRP20201323T1 (hr) Protutijela koja se specifično vežu na tl1a
Sieker et al. Direct bone morphogenetic protein 2 and Indian hedgehog gene transfer for articular cartilage repair using bone marrow coagulates
HRP20220760T1 (hr) Metabolički biomarkeri za predviđanje odgovaranja na spoj fgf-18
HRP20170110T1 (hr) Monoklonska protutijela
HRP20221284T1 (hr) Anti-pvrig antitijela i postupci uporabe
Neve et al. In vitro and in vivo angiogenic activity of osteoarthritic and osteoporotic osteoblasts is modulated by VEGF and vitamin D3 treatment
EA201992570A1 (ru) Составы на основе человеческих антител к rankl, а также способы их применения
HRP20240670T1 (hr) Postupci za predviđanje terapijske dobrobiti od anti-cd19 terapije kod pacijenata
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
Anderson et al. The synovial fluid proteome differentiates between septic and nonseptic articular pathologies
RU2015116674A (ru) Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции
Dopheide et al. Change of walking distance in intermittent claudication: impact on inflammation, oxidative stress and mononuclear cells: a pilot study
Haubruck et al. The treatment of nonunions with application of BMP-7 increases the expression pattern for angiogenic and inflammable cytokines: a matched pair analysis
WO2018055209A3 (en) Method for the diagnosis of acute pancreatitis (ap) by detection of glycoprotein 2 isoform alpha (gp2a)
EP4261224A4 (en) CD73 antigen-binding protein and use thereof
JP2016520583A5 (cg-RX-API-DMAC7.html)
Tomey et al. Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: an analysis of intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI)